about
Gout--current diagnosis and treatmentSLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosusSLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and goutRisk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDsEULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studiesImmunoadsorption for connective tissue disease.T lymphocyte activation--an inside overview.Understanding deficient elimination of uric acid.Defective removal of ribonucleotides from DNA promotes systemic autoimmunity.Increased transendothelial migration of scleroderma lymphocytes.Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice.Engineering anticancer T cells for extended functional longevity.Periodic fever syndromes--a clinical overview.Autoimmunity and rheumatoid arthritis.International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis.Anti-cytokine therapy in systemic lupus erythematosus.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Mixed connective tissue disease: what is behind the curtain?European consensus statement on the terminology used in the management of lupus glomerulonephritis.Immunoadsorption for systemic lupus erythematosus.Therapeutic blockade of TNF in patients with SLE-promising or crazy?Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Role of interleukin-6 in stress, sleep, and fatigue.Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceImmunoadsorption in Autoimmune Diseases Affecting the Kidney.Toward new criteria for systemic lupus erythematosus-a standpoint.Parvovirus infection in early arthritis.[Still's disease in children and adults].EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes.[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells.[Management of systemic lupus erythematosus].A 3-day delay in synovial fluid crystal identification did not hinder the reliable detection of monosodium urate and calcium pyrophosphate crystals.Vaccination under TNF blockade - less effective, but worthwhile.Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma.
P50
Q24644156-57CCDD2A-C896-4386-9A92-72462F8AA6DBQ24804939-13157340-C058-498E-AE33-C5E49D8A6EA2Q28119164-CFBF9194-E216-4180-B831-B690ED16C2B7Q33731689-CDFC1957-409A-4254-8F92-FC21D40E0BAEQ34132211-DB44C369-064F-48FB-9755-89096C40F55EQ34187282-D8613CB5-B1EC-4995-A477-5A2C8520D3FDQ34324839-363E73C3-E620-4A1D-8264-6B8CE5E9B754Q34567937-1780B171-5C27-4D6E-BB7A-97882D71FB99Q34844882-661DD1C0-C03B-4431-A81F-DFE339010449Q35242453-91453D61-096B-4A49-AD8B-B0B33BCE10A6Q35554086-235CEA31-82EF-40F8-9F33-F5B0343DE74FQ35642120-A72CDEEC-CFD4-40BB-8587-C562DDB83411Q35832907-AA0FEB94-B9EB-481B-B08C-DC1B0B3F017FQ35839214-D9903EC7-E5BC-40B5-883F-F3BD08043348Q35862380-629CB82D-332F-4EE3-AEB8-2C6B1EDC8452Q36084879-D9D5DD5D-46FE-43B7-B24B-C190848392B0Q36088040-C849D66B-D33A-463E-B395-CDF4974D90ACQ36302245-F2C3C794-D94D-42A3-A145-E1216380E47BQ37027965-8F793A5A-0366-4E01-9A28-212BE67E5FFDQ37391863-F37C5279-0863-444B-94FC-285BCC77927BQ37686732-431156C2-3838-4D0D-ADAC-4487FDEF9208Q37881012-8C6DE56D-9C7D-4EB5-8D0C-5CB2BB101510Q37954539-88B7E681-D62D-45BB-B628-F5FD287275F0Q38028589-163EDAAD-8FC3-4F2F-8F9A-C19436DC412CQ38152919-6689AA6B-E8A6-424A-BB2F-8728CE1CE86EQ38205079-7D75696F-5F36-4334-90AF-4A46AD8CB8FBQ38476881-CDEF0748-C160-44C6-839C-EF485FAC4DB1Q38597538-C83AC501-BAB1-4DD7-A48B-3F02CD889126Q38851089-4E070E4F-E32F-4E5B-9B0C-417AD9562703Q39990512-868694B0-89D1-4AC2-8887-C04613624E9DQ40045645-7BA86800-C195-4248-B143-BC01246C2F1CQ40305889-4051C64A-BCD4-4892-B278-0F9FBD161E8CQ40332155-BD358E29-DCE2-4BC6-8941-99AEFC45D982Q40647432-41C789FB-326E-4921-A3D9-079BF0CD9DFBQ40826525-DCEE2506-91F8-4993-85B4-94A57C6551F0Q41823791-FAF0A5FC-1252-4576-AA5F-C5050647FAC7Q41914056-7F548F38-E0D3-4850-87F7-4F5C5ED18A17Q42254346-CCCC888C-CC5F-4A14-8EE1-DE7B1AFBAAFFQ42326332-9E417A7E-E9E0-462C-8414-81100C0F973BQ42737198-575F24A8-819A-41CF-9967-24488D58954C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Martin Aringer
@ast
Martin Aringer
@en
Martin Aringer
@es
Martin Aringer
@nl
Martin Aringer
@sl
type
label
Martin Aringer
@ast
Martin Aringer
@en
Martin Aringer
@es
Martin Aringer
@nl
Martin Aringer
@sl
prefLabel
Martin Aringer
@ast
Martin Aringer
@en
Martin Aringer
@es
Martin Aringer
@nl
Martin Aringer
@sl
P214
P106
P21
P214
P31
P496
0000-0003-4471-8375
P735
P7859
viaf-67555398